Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.34 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16877599 | 1.00 | CHEK1 (0.34) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| Hydrochloric Acid SCHEMBL22394950 | 0.97 | CHEK1 (0.33) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL34475539 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL21573995 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL25231616 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL25229684 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL20104746 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL16877500 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL1286818 | 0.97 | — | — | |
| SCHEMBL28254 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-06-09 | — | — | US | disclosed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CHEK1 3061/4885AURKA 1849/4885RPS6KA5 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.